Intensive glycemic control (A1c ~ 7%) in patients with Type 2 diabetes mellitus has no significant effect on the rates of major cardiovascular events, death, peripheral neuropathy, and retinopathy compared with standard therapy (A1c ~ 8.5%) when measured within a mean 5.6 year treatment period. Intensive glycemic control does decrease the progression of albuminuria (P= 0.01) in this treatment window, but is associated with higher overall rates of adverse events (P = 0.05), including hypoglycemia (P < 0.001) and dyspnea (P = 0.006).
The information provided in this handout does not necessarily reflect the views of the University of Minnesota Medical School physicians and faculty. These materials are provided for informational purposes only and are in no way intended to take the place of the advice and recommendations of your personal health care provider. You use the information provided in these handouts at your own risk.
Intensive glycemic control in Type 2 diabetes mellitus has both benefits and risks: a review of the VADT study.
Retrieved from the University of Minnesota Digital Conservancy,
Content distributed via the University of Minnesota's Digital Conservancy may be subject to additional license and use restrictions applied by the depositor.